Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics

13.03.2014 / Fierce Pharma

One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis are promising to launch their versions as soon as Pfizer's monopoly expires.

Cover_HCLS_Ireland LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: